You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Bendamustine for the first-line treatment of chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • Reference number: TA216
  • Published:  23 February 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Appendix A - Decision paper presented to the Institute's Guidance Executive

Appendix A - Decision paper presented to the Institute's Guidance Executive

Appendix A - Decision paper presented to the Institute's Guidance Executive
03 March 2014
(103 Kb 30 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 25 March 2014

Back to top